MediciNova US patent for method of treating progressive MS
Posted: Mon Feb 06, 2012 1:55 am
MediciNova Inc, a biopharmaceutical company, has received a Notice of Allowance from the US Patent and Trademark Office for a pending patent application, which covers the use of ibudilast for the treatment of progressive forms of multiple sclerosis.
Ibudilast (MN-166), is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, neuropathic pain, and drug addiction.
A patent maturing from this allowed patent application is expected to expire no earlier than early 2029 and covers a method of treating primary progressive multiple sclerosis (PPMS) or secondary progressive MS (SPMS) by administering ibudilast either alone or in combination with other drugs....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1311